Subtopic Deep Dive
Mitochondrial Targeting by Nuclear Receptors in PD
Research Guide
What is Mitochondrial Targeting by Nuclear Receptors in PD?
Mitochondrial targeting by nuclear receptors in Parkinson's disease (PD) examines non-genomic actions of receptors like Nurr1 on mitochondrial dynamics, fission-fusion balance, bioenergetics, and mitophagy in dopaminergic neurons.
This subtopic focuses on nuclear receptors modulating mitochondrial function in PD models, including toxin-induced dopaminergic cell loss (Jiang et al., 2012; 246 citations). Research highlights mitochondrial impairment in PD pathogenesis, with potential therapeutic targeting via nuclear receptor pathways (Puspita et al., 2017; 470 citations). Over 10 key papers from 2009-2021 address related mechanisms, though direct Nurr1-mitochondria studies remain limited in the corpus.
Why It Matters
Mitochondrial dysfunction underlies dopaminergic neuron death in PD, making nuclear receptor modulation a therapeutic target for restoring bioenergetics and mitophagy (Puspita et al., 2017; Jiang et al., 2012). In toxin models, interventions like Dl-3-n-Butylphthalide ameliorate mitochondrial impairment and NLRP3 inflammasome activation, preserving neuronal viability (Que et al., 2021). Parkin regulation of dopamine utilization in iPSC-derived neurons links mitochondrial control to PD progression, informing disease-modifying strategies (Jiang et al., 2012; AlDakheel et al., 2013).
Key Research Challenges
Linking NRs to Mitochondria
Direct evidence for nuclear receptors like Nurr1 targeting mitochondria in PD dopaminergic cells is sparse. Studies emphasize genomic actions, overlooking non-genomic mitochondrial signaling (Jiang et al., 2012). Toxin models show mitochondrial deficits but rarely specify receptor involvement (Puspita et al., 2017).
Quantifying Fission-Fusion Dynamics
Measuring nuclear receptor effects on mitochondrial fission-fusion in live PD neurons requires advanced imaging. Current papers describe general oxidative stress impacts without receptor-specific dynamics (Lesly Puspita et al., 2017). iPSC models aid but lack high-throughput NR modulation (Jiang et al., 2012).
Translating to Human PD Models
Animal and cell models dominate, with limited human iPSC data tying NRs to mitophagy in PD. Heterogeneity in PD progression complicates validation (Konnova and Swanberg, 2018). Therapeutic candidates like cystatin C show promise but need NR pathway integration (Zou et al., 2017).
Essential Papers
Neuroinflammation in Parkinson’s disease and its potential as therapeutic target
Qinqin Wang, Yingjun Liu, Jiawei Zhou · 2015 · Translational Neurodegeneration · 844 citations
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Marta Pajares, Ana I. Rojo, Gina Manda et al. · 2020 · Cells · 711 citations
Parkinson’s disease (PD) is a common neurodegenerative disorder primarily characterized by the death of dopaminergic neurons that project from the substantia nigra pars compacta. Although the molec...
Oxidative stress and cellular pathologies in Parkinson’s disease
Lesly Puspita, Sun Young Chung, Jaewon Shim · 2017 · Molecular Brain · 470 citations
Parkinson's disease (PD) is a chronic and progressive neurodegeneration of dopamine neurons in the substantia nigra. The reason for the death of these neurons is unclear; however, studies have demo...
Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells
Houbo Jiang, Yong Ren, Eunice Y. Yuen et al. · 2012 · Nature Communications · 246 citations
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
Michiel Van Bulck, Ana Sierra‐Magro, Jesús Alarcón-Gil et al. · 2019 · International Journal of Molecular Sciences · 167 citations
Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk fac...
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
Amaal AlDakheel, Lorraine V. Kalia, Anthony E. Lang · 2013 · Neurotherapeutics · 149 citations
Animal Models of Parkinson’s Disease
Elena A. Konnova, Maria Swanberg · 2018 · Codon Publications eBooks · 115 citations
Parkinson’s disease (PD) is a heterogenous disease with a varying age of onset, symptoms, and rate of progression. This heterogeneity requires the use of a variety of animal models to study differe...
Reading Guide
Foundational Papers
Start with Jiang et al. (2012; 246 citations) for parkin-mitochondria in iPSC dopaminergic neurons, foundational for bioenergetics. Follow with AlDakheel et al. (2013; 149 citations) for pathogenesis-targeted therapies linking to mitochondrial modulation.
Recent Advances
Que et al. (2021; 104 citations) details mitochondrial rescue in PD models; Pajares et al. (2020; 711 citations) covers inflammation-mitochondria intersections relevant to NR signaling.
Core Methods
Toxin-induced models (rotenone, NLRP3 activators) per Que et al. (2021); iPSC differentiation for dopamine neurons (Jiang et al., 2012); autophagy assays for mitophagy quantification.
How PapersFlow Helps You Research Mitochondrial Targeting by Nuclear Receptors in PD
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to find papers on Nurr1-mitochondria interactions in PD, graphing citation networks via citationGraph from seeds like Jiang et al. (2012; 246 citations). findSimilarPapers expands to related mitophagy regulators in dopaminergic models.
Analyze & Verify
Analysis Agent employs readPaperContent on Que et al. (2021) to extract mitochondrial impairment data, then verifyResponse with CoVe checks claims against Puspita et al. (2017). runPythonAnalysis performs statistical verification of bioenergetics metrics across papers, with GRADE grading for evidence strength in toxin models.
Synthesize & Write
Synthesis Agent detects gaps in NR-mitochondria links, flagging contradictions between genomic vs. non-genomic actions. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Jiang et al. (2012), with latexCompile for figures and exportMermaid for fission-fusion pathway diagrams.
Use Cases
"Analyze mitochondrial dynamics in PD dopaminergic neurons from toxin models."
Research Agent → searchPapers('mitochondrial dynamics PD toxin models') → Analysis Agent → runPythonAnalysis (pandas aggregation of bioenergetics data from 5 papers) → researcher gets CSV of quantified fission-fusion metrics.
"Draft LaTeX review on nuclear receptors rescuing mitochondria in PD."
Synthesis Agent → gap detection (NR-mitophagy gaps) → Writing Agent → latexEditText + latexSyncCitations (Jiang 2012, Que 2021) + latexCompile → researcher gets compiled PDF with synced bibliography.
"Find code for iPSC dopaminergic neuron mitochondrial assays in PD papers."
Research Agent → paperExtractUrls (Jiang 2012) → Code Discovery → paperFindGithubRepo + githubRepoInspect → researcher gets annotated GitHub repos with mitophagy simulation scripts.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PD mitochondrial papers, chaining searchPapers → citationGraph → structured report on NR targeting. DeepScan applies 7-step analysis with CoVe checkpoints to verify Nurr1-mitophagy claims across Jiang et al. (2012) and Que et al. (2021). Theorizer generates hypotheses on non-genomic NR actions from literature patterns in dopaminergic bioenergetics.
Frequently Asked Questions
What defines mitochondrial targeting by nuclear receptors in PD?
It refers to non-genomic actions of receptors like Nurr1 on mitochondrial dynamics, fission-fusion, bioenergetics, and mitophagy in dopaminergic neurons (Jiang et al., 2012).
What are key methods in this subtopic?
Toxin models (MPTP, rotenone) assess mitochondrial impairment; iPSC-derived dopaminergic neurons quantify dopamine utilization and mitophagy (Jiang et al., 2012; Que et al., 2021).
Name top papers on mitochondria-PD links.
Jiang et al. (2012; 246 citations) on parkin in iPSC neurons; Puspita et al. (2017; 470 citations) on oxidative stress; Que et al. (2021; 104 citations) on mitochondrial rescue.
What open problems exist?
Scarce direct Nurr1-mitochondria evidence in human PD models; need for high-throughput NR modulators targeting fission-fusion (Konnova and Swanberg, 2018).
Research Nuclear Receptors and Signaling with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mitochondrial Targeting by Nuclear Receptors in PD with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers
Part of the Nuclear Receptors and Signaling Research Guide